Buprenorphine

References

• Substance Abuse and Mental Health Services Administration. Buprenorphine information website 2002, Available at http://www.buprenorphine.samhsa.gov/AccessedFebruary 1, 2004
   Google Scholar
• American Association for the Treatment of Opioid Dependence website, Available at: http://www.aatod.org/nr1999.htm#associationAccessed February 2004
   Google Scholar
• Subutex (buprenorphine)/Suboxone (buprenorphine/naloxone). Product information. Reckitt Benckiser Pharmaceuticals, Inc, Richmond, VA 2002
   Google Scholar
• Stoller K B, Bigelow G E, Walsh S L, Strain E C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001; 154(3)230–42
   PubMed Web of Science ®Google Scholar
• Walter D S, Inturrisi C E. Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. Buprenorphine: Combating Drug Abuse With a Unique Opioid, A Cowan, J W Lewis. Wiley-Liss, New York 1995
   Google Scholar
• Harris D S, Jones R T, Welm S, Upton R A, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000; 61: 85–94
   PubMed Web of Science ®Google Scholar
• Ajir K, Chiang C N, Huber A, Ling W. Pharmacokinetics of Liquid vs. Tablet Buprenorphine. Problems of Drug Dependence, 1999: Proceedings of the 61st Annual Scientific Meeting. 2000, L S Harris. NIDA, Washington, DC, 160, Research Monograph 180
   Google Scholar
• Nath R P, Upton R A, Everhart E T, et al. Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999; 39: 619–23
   PubMed Web of Science ®Google Scholar
• Jones R T, Mendelson J, Upton R. An open-label, partially blinded, balanced 4X4 latin square crossover study to evaluate the pharmacokinetic and dose-proportionality of buprenorphine when administered in sublingual tablets alone or in combination with naloxone in nondependent opiate users. 1997, NIDA Contract N01DA-4–8306 report, pharmacokinetic and pharmacodynamic studies for medication development.
   Google Scholar
• Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281: 428–33
   PubMed Web of Science ®Google Scholar
• Proceedings of the 60th Annual Scientific Meeting of the College on Problems of Drug Dependence. Buprenorphine-naloxone (4:1) combinationdose proportionality after sublingual administration, Scottsdale, 1998, College on Problems of Drug Dependence
   Google Scholar
• Jones R T, Upton R. Subchronic buprenorphine study: Sublingual buprenorphine/naloxone interactions. Pharmacokinetic and pharmacodynamic studies for medication development. 1997, NIDA Contract N01DA-4–8306 report. 1997
   Google Scholar
• Holford N H. Pharmacokinetics and pharmacodynamics of buprenorphine and naloxone in opiate-dependent subjects. Clin PharmacolTher 2000; 67: 139
   Google Scholar
• Hand C W, Sear J W, Uppington J., Ball M J, McQuay H J, Moore R A. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64: 276–82
   PubMed Web of Science ®Google Scholar
• Kosten T R, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181: 358–64
   PubMed Web of Science ®Google Scholar
• Johnson R E, Eissenberg T, Stitzer M L, Strain E C, Liebson I A, Bigelow G E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40: 17–25
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson D R, Charuvastra C, Klett C J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53: 401–7
   PubMed Web of Science ®Google Scholar
• Pani P P, Maremmani I, Pirastu R, Tagliamonte A, Gessa G L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60(1)39–50
   PubMed Web of Science ®Google Scholar
• Fudala P J, Bridge T P, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10)949–58
   PubMed Web of Science ®Google Scholar
• Strain E C, Stitzer M L, Liebson I A, Bigelow G E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994; 151(7)1025–30
   PubMed Web of Science ®Google Scholar
• Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94(9)1337–347
   PubMed Web of Science ®Google Scholar
• Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitzer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New Engl J Med 2000; 343: 1290–97
   PubMed Web of Science ®Google Scholar
• Petitjean S, Stohler R, Deglon J J, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62(1)97–104
   Google Scholar
• Mattick R P, Ali R, White J M, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4)441–52
   PubMed Web of Science ®Google Scholar
• Janiri L, Mannelli P, Persico A M, Serretti A, Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994; 36(2)139–45
   PubMedGoogle Scholar
• Cheskin L J, Fudala P J, Johnson R E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36(2)115–21
   PubMed Web of Science ®Google Scholar
• O'Connor P G, Carroll K M, Shi J M, Schottenfeld R S, Kosten T R, Rounsaville B J. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 1997; 127(7)526–30
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Bell J, Bammer G, Jolley D J, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002; 97(11)1395–404
   PubMed Web of Science ®Google Scholar
• Ajayi A A, Campbell B C, Rubin P C, et al. Effect of naloxone on the actions of captopril. Clin Pharmacol Ther 1985; 38: 560–65
   PubMed Web of Science ®Google Scholar
• Rubin P C, Millar J A, Sturani S, et al. The influence of naloxone on the circulatory effects of captopril. Br J Clin Pharmacol 1984; 17: 713–17
   PubMed Web of Science ®Google Scholar
• Farsang C, Kapocsi J, Juhasz I, et al. Possible involvement of an endogenous opioid in the antihypertensive effect of clonidine in patients with essential hypertension. Circulation 1982; 66: 1268–72
   PubMed Web of Science ®Google Scholar
• Wasserberger J, Ordog G J. Naloxone-induced hypertension in patients on clonidine (letter). Ann Emerg Med 1988; 17: 557
   Google Scholar
• Gremse D A, Ahman M, Boerth R C. Hypertension associated with naloxone treatment for clonidine poisoning. J Pediatr 1986; 108: 776–78
   PubMed Web of Science ®Google Scholar
• Loimer N, Schmid R, Lenz K, et al. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990; 157: 748–52
   PubMed Web of Science ®Google Scholar
• Charney D S, Heninger G R. Alpha-2-adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects. Arch Gen Psychiatry 1986; 43(11)1037–41
   Google Scholar
• Office of Applied Studies, Substance Abuse and Mental Health Services Administration National Household Survey on Drug Abuse. 1999
   Google Scholar
• Personal communication CSAT Buprenorphine Information Center, Substance Abuse and Mental Health Services Administration. February, 2004
   Google Scholar